Member Info for RayPointer

something like this you mean

https://www.ebaumsworld.com/images/the-biggest-gold-nugget-ever-found/81500128/

https://www.trinitydelta.org/research-notes/a-fresh-impetus-in-delivering-immune-oncology-vaccines/

See the paragraph entitled "Combination therapies are seen as the way forward"

"Cancer immunotherapy aims to identify and correct the imbalance so that the cycle becomes self-sustaining again. The difficulty is firstly to ensure a treatment does not overly amplify the immune response, causing an exaggerated autoimmune reaction, but, more challengingly, to ensure tumour cells do not find alternative pathways and so escape. "

Lindy has to provide a balance whereby the immune response is not "overamplified". This involves tipping of the immune response to something that is enough to reduce the tumours but in a controlled manner. I think Wild has mentioned this previously in posts.
I take this to mean that patients will wait a varying length of time before tumours start to reduce.

This can we seen in the famous SCIB1 swim chart

https://www.scancell.co.uk/scib1-iscib1

For some patients 3 doses was enough to become disease-free, whereas for others a lot more than 3 doses were required.

Also, it should be noted that Modi1 is expected to produce a memory effect whereas CIs do not provide any memory effect.

I recall that Lindy was asked the very same question about Modi1 at a presentation some years ago.
"Does the mouse data guarantee success in a clinical trial?" or similar
Her short answer was
"Absolutely not"
I don't think that Lindy will be drawn on speculating on probabilities of success of the Modi1 trial.
However she did say she was very excited :-)

The irony of the TD valuation is that is matters not how many Glymab/Avidimab deals are signed, until the products progress into the clinic the valuation stays the same. That's how I read it anyway.

Ivy
As far as ABs are concerned, the main target was the RDB area of the spike protein.
So no surprise here.
T Cells are another matter which targeted both N and S proteins.

I think we have to wait until the results are published in a scientific journal to get the complete picture.
I was under the impression that this was Lindy's intention.

I would be very disappointed with £7.99 :-)

Kashdog

I might be wrong, but I think, in this post C7, was referring to the fact that this was a genuine patient on the Modi1 trial.
He was not referring to the subsequent distress this patient felt once she realised that her posts were being discussed elsewhere (on this BB).

"I was thinking of Part B of CT 1 which is was to be held in the UK"

Hi LL
I think that got abandoned when they changed the South Africa trial to take into account the recruitment difficulties resulting from the spread of the omicron variant.
I don't think we ever had an announcement to that effect but I may be wrong.

https://www.linkedin.com/in/jean-michel-cossery-91b67215/

He has certainly got around a bit. Currently also non-exec director in 4 other companies

The pre-surgery cohorts will be very interesting, particularly after the spectacular success of the SCIB1 trial post surgery.
The aim seems to be for the killer CD4 TCells to stop any recurrence of the cancer dead in its tracks.

"we know trial patients have seen significant reductions in tumor size (confirmed by LD at the AGM)"

Yes,I heard that too, but I wondered whether it was a slip of the tongue. I'm surprised she wasn't asked about this.
Time will tell of course.

A clear case of monkeyism :-)

Looks like a load of codswallop to me

I think it was a good deal too, and it was nice to see that Genmab repeated all Scancell's tests and were still keen to deal.
Two groups of scientists come to the same conclusion that SC129 its worth pursuing :-)

Great post empty at 9:13
I would add that there is little point in doing a blow by blow account of the how the trials are going.
The numbers simply aren't near to statistical significance at this point in time.

The other point that Lindy made is that pharma are not satisfied with the headline news that PIs are interested in (tumour regression). Additionally they are also interested that the expected sequence of events is actually taking place.

This evidence for the Modi1 trial could be:

1) Activation of cytotoxic CD4 T Cells
2) Infiltration into the tumour by the T Cells
3) Inflammation caused by interferon gamma emitted by the T Cells
4) Expression of the target epitope on the tumour cell
5) Obviously, killing of the tumour cell
6) Production of memory T Cells

The Oxford team may be collecting this evidence before reporting progress of trials.

"Guess they’ll need to find other things to combine with Keytruda ??"
Modi2 may be the answer

https://www.scancell.co.uk/modi-2

"NPM plays a variety of roles in cellular metabolism and overexpression of NPM has been reported in multiple human cancers including those of the pancreas, prostate, liver, colon, stomach and thyroid."

Never expect Scancell news to be on time.
If you remember this, you will not be disappointed.
If Moditope is working, the later this particular item of new is, the better it will be.
Just be happy and clap :-)

:-)

With modi1 it's clear that, if it is successful, it will generate tremendous interest amongst big Pharmas. With Covidity it is less clear what level of interest there will be. I would guess zero interest from short sighted governments especially the UK government. CEPI may be a different matter though.